Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Upstream Bio, Inc. ( (UPB) ) just unveiled an announcement.
On February 11, 2026, Upstream Bio hosted a webcast to present top-line results from its Phase 2 VALIANT trial of verekitug in severe asthma, reporting that the study met its primary endpoint of reducing annualized asthma exacerbation rates. Verekitug given at 100 mg every 12 weeks and 400 mg every 24 weeks achieved statistically significant and clinically meaningful reductions in exacerbations, alongside improvements in lung function and exhaled nitric oxide, while being generally well tolerated with a safety profile consistent with prior studies.
The company positioned these data as reinforcing verekitug’s differentiated TSLP-receptor–targeted profile and supporting its broader development program across severe asthma, CRSwNP and COPD. Together with ongoing and planned trials and a reported cash position expected to fund operations through 2027, the results underscore Upstream Bio’s bid to secure a role in an anticipated multibillion-dollar global biologics market for severe respiratory diseases.
The most recent analyst rating on (UPB) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.
Spark’s Take on UPB Stock
According to Spark, TipRanks’ AI Analyst, UPB is a Neutral.
The score is driven primarily by strong technical momentum (price above key moving averages with positive MACD and supportive RSI). This is tempered by weak financial performance typical of an early-stage biotech—expanding losses and worsening cash burn—despite a low-debt balance sheet. Valuation is also constrained by negative earnings (negative P/E) and no stated dividend yield.
To see Spark’s full report on UPB stock, click here.
More about Upstream Bio, Inc.
Upstream Bio, Inc. is a clinical-stage immunology company focused on severe respiratory diseases, including severe asthma, chronic rhinosinusitis with nasal polyps and COPD. Its lead asset, verekitug, is described as the only known clinical-stage antagonist of the TSLP receptor, with trials designed using randomized, placebo-controlled, registration-enabling endpoints and targeting large, growing biologics markets.
Average Trading Volume: 585,306
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.42B
See more insights into UPB stock on TipRanks’ Stock Analysis page.